News + Resources
Keep up with the latest
Featured
Epigenetic editors are a gentler form of gene editing
February 24, 2025
The Economist
Epigenetic editors are a gentler form of gene editing
February 24, 2025
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
All Stories
Press Release
Scribe Therapeutics to Participate in Upcoming Investor Conferences in May and June
May 22, 2023
Read Now
Press Release
Scribe Therapeutics to Participate in Upcoming Investor Conferences in May and June
May 22, 2023
Read Now
Press Release
Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 19, 2023
Read Now
Press Release
Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 19, 2023
Read Now
News
Scribe Inks CRISPR Gene-Editing Deal with Prevail
May 19, 2023
Bloomberg
Read Now
Press Release
Scribe Inks CRISPR Gene-Editing Deal with Prevail
May 19, 2023
Bloomberg
Read Now
News
Scribe signs another big pharma deal
May 19, 2023
Evaluate
Read Now
Press Release
Scribe signs another big pharma deal
May 19, 2023
Evaluate
Read Now